CN1227033C - 采用抗神经营养蛋白剂治疗癌症的方法 - Google Patents

采用抗神经营养蛋白剂治疗癌症的方法 Download PDF

Info

Publication number
CN1227033C
CN1227033C CNB018058108A CN01805810A CN1227033C CN 1227033 C CN1227033 C CN 1227033C CN B018058108 A CNB018058108 A CN B018058108A CN 01805810 A CN01805810 A CN 01805810A CN 1227033 C CN1227033 C CN 1227033C
Authority
CN
China
Prior art keywords
neurotrophin
day
antibody
antibodies
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018058108A
Other languages
English (en)
Chinese (zh)
Other versions
CN1420785A (zh
Inventor
卡伦·J·布奇科维奇
克雷格·A·迪翁
希拉·J·米克尼奥茨基
布鲁斯·A·鲁杰里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of CN1420785A publication Critical patent/CN1420785A/zh
Application granted granted Critical
Publication of CN1227033C publication Critical patent/CN1227033C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNB018058108A 2000-02-29 2001-02-28 采用抗神经营养蛋白剂治疗癌症的方法 Expired - Fee Related CN1227033C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18594300P 2000-02-29 2000-02-29
US60/185,943 2000-02-29
US09/793,850 US6548062B2 (en) 2000-02-29 2001-02-27 Method of treating cancer with anti-neurotrophin agents
US09/793,850 2001-02-27

Publications (2)

Publication Number Publication Date
CN1420785A CN1420785A (zh) 2003-05-28
CN1227033C true CN1227033C (zh) 2005-11-16

Family

ID=26881613

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018058108A Expired - Fee Related CN1227033C (zh) 2000-02-29 2001-02-28 采用抗神经营养蛋白剂治疗癌症的方法

Country Status (13)

Country Link
US (1) US6548062B2 (enExample)
EP (1) EP1261372B1 (enExample)
JP (1) JP2003525253A (enExample)
CN (1) CN1227033C (enExample)
AT (1) ATE361100T1 (enExample)
AU (2) AU2001239913B2 (enExample)
CA (1) CA2401604C (enExample)
DE (1) DE60128208T2 (enExample)
ES (1) ES2286110T3 (enExample)
HK (1) HK1049961B (enExample)
MX (1) MXPA02008465A (enExample)
NZ (1) NZ521165A (enExample)
WO (1) WO2001064247A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
JP3773733B2 (ja) * 2000-01-13 2006-05-10 松下電器産業株式会社 陰極線管
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
CN1684708A (zh) * 2001-05-30 2005-10-19 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
US20060147450A1 (en) * 2002-10-04 2006-07-06 Shelton David L Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
JP4584713B2 (ja) * 2002-10-08 2010-11-24 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物
FR2846426B1 (fr) * 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
CN101014364B (zh) * 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
PL379983A1 (pl) * 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
US20050043215A1 (en) * 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
EA013614B1 (ru) * 2003-07-15 2010-06-30 Амджен Инк. Изолированное антитело к фактору роста нервов (ngf) и способы его применения
ES2616337T3 (es) * 2003-12-12 2017-06-12 Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
EP3372614B1 (en) * 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
NZ556157A (en) 2005-01-24 2009-09-25 Elan Pharma Int Ltd Specific binding members for NGF
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
RS53661B1 (sr) 2007-08-10 2015-04-30 Regeneron Pharmaceuticals, Inc. Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
US20110229485A1 (en) * 2008-05-21 2011-09-22 Centre National De La Recherche Scientfique (Cnrs) Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
JP2012515158A (ja) 2009-01-12 2012-07-05 武田薬品工業株式会社 癌の予防・治療剤
EA201190115A1 (ru) 2009-01-24 2012-02-28 ФИТОФАРМ ПиЭлСи Лечение расстройств, опосредованных нейротрофическим фактором
US8435523B2 (en) * 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
EP2547365A1 (en) 2010-03-17 2013-01-23 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
CA2808577C (en) 2010-08-19 2018-09-25 Abbott Laboratories Anti-ngf antibodies and their use
JP6105838B2 (ja) * 2010-08-24 2017-03-29 国立大学法人 岡山大学 疼痛の治療剤
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
AU2013271564A1 (en) 2012-06-06 2014-12-04 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
EP2859019B1 (en) 2012-06-08 2018-02-21 Glenmark Pharmaceuticals S.A. Humanized anti-trka antibodies with amino acid substitutions
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CA3093772C (en) 2018-03-12 2024-04-16 Zoetis Services Llc Anti-ngf antibodies and methods thereof
MX2024007088A (es) 2021-12-16 2024-08-22 Intervet Int Bv Anticuerpos caninizados contra el ngf humano.
EP4514998A1 (en) 2022-04-27 2025-03-05 Regeneron Pharmaceuticals, Inc. Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score
US20240310383A1 (en) 2023-03-17 2024-09-19 Regeneron Pharmaceuticals, Inc. Proteomic Risk Score For Osteoarthritis (OA)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1073264A (zh) 1991-11-12 1993-06-16 里珍纳龙药品有限公司 基于组织的特定的nt-3表达与受体结合的治疗和诊断方法
AU5102493A (en) 1992-09-11 1994-04-12 Cephalon, Inc. A method for the detection and treatment of prostate disease
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
EP0753013A1 (en) * 1994-03-29 1997-01-15 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Neurotrophin-6: a new member of the neurotrophin family

Also Published As

Publication number Publication date
AU2001239913B2 (en) 2005-12-08
HK1049961A1 (en) 2003-06-06
HK1049961B (en) 2007-09-14
ES2286110T3 (es) 2007-12-01
CA2401604A1 (en) 2001-09-07
MXPA02008465A (es) 2003-03-10
CA2401604C (en) 2011-05-24
WO2001064247A3 (en) 2002-02-14
EP1261372A2 (en) 2002-12-04
JP2003525253A (ja) 2003-08-26
NZ521165A (en) 2004-08-27
US20010046959A1 (en) 2001-11-29
EP1261372B1 (en) 2007-05-02
ATE361100T1 (de) 2007-05-15
DE60128208D1 (de) 2007-06-14
CN1420785A (zh) 2003-05-28
DE60128208T2 (de) 2008-01-10
US6548062B2 (en) 2003-04-15
AU3991301A (en) 2001-09-12
WO2001064247A2 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
CN1227033C (zh) 采用抗神经营养蛋白剂治疗癌症的方法
AU2001239913A1 (en) Method of treating cancer with anti-neurotrophin agents
AU687346B2 (en) A combination of anti-erbB-2 monoclonal antibodies and method of using
JP4620808B2 (ja) 突然変異上皮成長因子受容体を標的とする試薬および方法
US20120230991A1 (en) Methods and compounds for enhancing anti-cancer therapy
CN1878794A (zh) Ngf拮抗剂和阿片样药剂在治疗疼痛中的用途
KR20120089346A (ko) 높은 차단 활성을 갖는 항-Ｃ5ａ 결합 부분
JP2009155335A (ja) 抗癌療法のためのマクロファージマイグレーション阻害因子アンタゴニストの使用
CN1466464A (zh) 癌症治疗药
CN1639194A (zh) 抗癌抗体
EP2794659A1 (en) Human growth hormone receptor antagonist antibodies and methods of use thereof
CA2555694C (en) Anti-epcam immunoglobulins
JP2019527697A (ja) 癌を治療するためのグルカゴン受容体アンタゴニストとｐｉ３ｋ経路阻害剤との組み合わせ
JP2023512181A (ja) 癌を治療するためのｅｇｆｒ阻害剤とｒｏｒ１阻害剤の組み合わせ
KR20240095160A (ko) 인간화된 항-인간 βig-h3 단백질 및 이의 용도
US11629186B2 (en) Anti-CCL8 antibodies and uses thereof
CN113710321A (zh) 用于治疗癌症的方法和组合物
KR100204733B1 (ko) 인체 4-1비비 분자에 특이성이 있고 면역억제 효과를 갖는 모노클로날 항체
CN1871028A (zh) 通过施用神经生长因子拮抗剂和nsaid和含有它们的组合物治疗疼痛的方法
JP7698842B2 (ja) 糖尿病性自律神経障害の予防又は治療剤
Garrett Peptide-based B-cell epitope vaccines targeting HER-2/neu
HK1078590B (en) Novel anti-igf-ir antibodies and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051116

Termination date: 20170228

CF01 Termination of patent right due to non-payment of annual fee